170 related articles for article (PubMed ID: 19127502)
1. Targeting transcription factors for cancer therapy.
Frank DA
IDrugs; 2009 Jan; 12(1):29-33. PubMed ID: 19127502
[TBL] [Abstract][Full Text] [Related]
2. Targeting protein kinases in cancer therapy: a success?
Pearson MA; Fabbro D
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1113-24. PubMed ID: 15606337
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of drug inhibition of signalling molecules.
Sebolt-Leopold JS; English JM
Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
[TBL] [Abstract][Full Text] [Related]
4. Id genes and proteins as promising targets in cancer therapy.
Fong S; Debs RJ; Desprez PY
Trends Mol Med; 2004 Aug; 10(8):387-92. PubMed ID: 15310459
[TBL] [Abstract][Full Text] [Related]
5. The future of targeted therapies in ovarian cancer.
Banerjee S; Gore M
Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
[TBL] [Abstract][Full Text] [Related]
6. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics.
Kirkland LO; McInnes C
Biochem Pharmacol; 2009 May; 77(10):1561-71. PubMed ID: 19167366
[TBL] [Abstract][Full Text] [Related]
7. Current and future approaches for the therapeutic targeting of metastasis (review).
Germanov E; Berman JN; Guernsey DL
Int J Mol Med; 2006 Dec; 18(6):1025-36. PubMed ID: 17089005
[TBL] [Abstract][Full Text] [Related]
8. Targeted cancer therapeutics.
Hait WN; Hambley TW
Cancer Res; 2009 Feb; 69(4):1263-7; discussion 1267. PubMed ID: 19208830
[TBL] [Abstract][Full Text] [Related]
9. Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock".
Sharma SV; Settleman J
Biochem Pharmacol; 2010 Sep; 80(5):666-73. PubMed ID: 20211150
[TBL] [Abstract][Full Text] [Related]
10. Phosphatases as targets for cancer treatment.
Lazo JS; Wipf P
Curr Opin Investig Drugs; 2009 Dec; 10(12):1297-304. PubMed ID: 19943201
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
12. The promise and challenges of targeting RSK for the treatment of cancer.
Stratford AL; Dunn SE
Expert Opin Ther Targets; 2011 Jan; 15(1):1-4. PubMed ID: 21142801
[No Abstract] [Full Text] [Related]
13. Rational drug design.
Mandal S; Moudgil M; Mandal SK
Eur J Pharmacol; 2009 Dec; 625(1-3):90-100. PubMed ID: 19835861
[TBL] [Abstract][Full Text] [Related]
14. Decrease in RelA phosphorylation by inhibiting protein kinase A induces cell death in NF-kappaB-expressing and drug-resistant tumor cells.
Manna SK; Gangadharan C
Mol Immunol; 2009 Apr; 46(7):1340-50. PubMed ID: 19128834
[TBL] [Abstract][Full Text] [Related]
15. Strategies to improve drug delivery in bladder cancer therapy.
Wirth M; Plattner VE; Gabor F
Expert Opin Drug Deliv; 2009 Jul; 6(7):727-44. PubMed ID: 19538035
[TBL] [Abstract][Full Text] [Related]
16. Cancer chemopreventive agents-drugs for the 21st century?
Baer-Dubowska W
Acta Pol Pharm; 2006; 63(5):369-73. PubMed ID: 17357586
[TBL] [Abstract][Full Text] [Related]
17. PI3K inhibitors for cancer treatment: where do we stand?
Maira SM; Stauffer F; Schnell C; García-Echeverría C
Biochem Soc Trans; 2009 Feb; 37(Pt 1):265-72. PubMed ID: 19143644
[TBL] [Abstract][Full Text] [Related]
18. Transcription factors and neoplasia: vistas in novel drug design.
Karamouzis MV; Gorgoulis VG; Papavassiliou AG
Clin Cancer Res; 2002 May; 8(5):949-61. PubMed ID: 12006506
[TBL] [Abstract][Full Text] [Related]
19. [Molecular targeting drugs--present status and future development].
Kuwano M; Fujii T; Ono M; Izumi H; Kohno K
Nihon Rinsho; 2004 Jul; 62(7):1211-5. PubMed ID: 15283135
[TBL] [Abstract][Full Text] [Related]
20. Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.
Wang H; Han H; Mousses S; Von Hoff DD
Semin Oncol; 2006 Aug; 33(4):513-20. PubMed ID: 16890805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
